Phase 2 N=42 Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women
DCIS
Primary: Number of Participants With a Change in Ki-67 Level — 15; 5; 3 Participants — p=0.004
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=46 Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer
Breast Neoplasms
Primary: Percent Change in Mammographic Density at 1 Year on Exemestane — -2.4 percent change from baseline
Phase 4 N=17 A Study to Optimize Growth Hormone Dosing in Children With Chronic Kidney Disease by Measuring IGF-1 Levels in Blood
Kidney Failure, Chronic · Growth Hormone Deficiency
Primary: The Change in Amount of Insulin Like Growth Factor (IGF-I) Generated (Day 8-day 1) — 115; 129 mcg/L
Phase 3 N=4,884 Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer
Breast Cancer
Primary: Disease-free Survival (DFS) — 87.5; 85.8 percentage of patients — p=.31
N/A N=51 Psychosocial Outcomes in Online Cancer Support Groups
Breast Cancer
Primary: Scores on the Personal Resource Questionnaire 85. — 50.22; 53.44 Scores on a scale — p=.315
N/A N=271 Promoting Breast Cancer Screening in Women Who Survived Childhood Cancer
Breast Neoplasms · Early Detection of Cancer
Primary: Percentage of Women Who Completed a Breast MRI and Mammogram — 8.9; 22.0; 17.8 percentage of participants — p=0.019
Phase 1 N=30 Role of Endogenous Estrogen in Growth-Hormone Regulation in Postmenopausal Women
Healthy
Primary: Mean Baseline GH Concentration — 0.23; 0.096 ug/L — p=<0.05
Phase 2 N=3 The Effect of GHRH Therapy on Myocardial Structure and Function in Congestive Heart Failure
Congestive Heart Failure
Primary: PP1- Serum IGF-1 Levels, DXA, Resting Metabolic Rate, Total Body Water, 3-D Echo, Cardiac MRI, Dobutamine Stress Echocardiogram, Ergometry, General Health Assessment…
N/A N=6,013 Evaluation of Human Papilloma Virus (HPV) Self-testing to Increase Screening Uptake
Cervical Intraepithelial Neoplasia
Primary: Screening Uptake — 2519; 0; 2618; 599 participants
Phase 3 N=295 Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive
Estrogen Receptor Positive · HER2 Positive Breast Carcinoma · HER2/Neu Negative
Primary: Progression-free Survival (PFS) — 4.7; 3.8 months — p=0.37
Phase 4 N=79 Exercise and Phytoestrogens: Effect on Factors Predisposing to Cardiovascular Disease(CVD) in Postmenopausal Women
Overweight
Primary: Body Composition: Dual-energy X-ray Absorptiometry Method — 44.5; 48.8; 43.8; 46.6 percent of total fat mass
Phase 2 N=72 Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer
Breast Cancer
Primary: Change in Ki-67 Levels From Baseline (Pre) to Day 28 (Post) Biopsy Samples — -1.3632; -1.6237 log-transformed Ki67% — p=0.6202
N/A N=18 The Effects of Resveratrol and Acute Exercise on Endothelial Function in Postmenopausal Women
Endothelial Dysfunction
Primary: Percent Change in Brachial Artery Flow-mediated Dilation at Each Time Point — 4.11; 6.93; 5.86; 3.20 Percent Change
Phase 2 N=24 Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the Norton-Simon Mathematical Method in Patients With HER2 Overexpressed/Amplified, Trastuzumab (Herceptin) -Refractory, Metastatic Breast Cancer
Breast Cancer
Primary: Estimate Efficacy of Capecitabine 7/7 in Combination With Lapatinib in Patients With HER2 Overexpressed/Amplified, Trastuzumab-refractory, Metastatic Breast Cancer as…
Phase 2 N=71 A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer
Breast Cancer
Primary: Phase I Cohort A: Maximum Tolerated AZD0530 Daily Dose Used in Combination With Daily Oral Anastrozole — 1; 175 mg/day oral dose